Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 31, 2026

Back to the front page

From X

@MultiplesCap

Multiples Capital on X

Not an AI expert by any stretch, but wonder if US labs actually coordinate to "pace the frontier," it could be a stealth negative for Nvidia’s top-line growth rate. Here’s why: Flattening the Frontier Race: If scaling massive base models is intentionally delayed for alignment, the panic to hoard the newest, most expensive contiguous GPU clusters cools down. Shift to Post-Training & RL: Progress shifts to squeezing intelligence out of existing models via synthetic data and self-play. This relies on inference-class rollout fleets rather than cutting-edge pre-training mega-clusters. The Verification Layer: Evaluating, sandboxing, and grading all that synthetic RL data requires massive CPU compute .... benefitting $INTC Less brute-force pre-training = extended hardware refresh cycles and a normalized upgrade curve for $NVDA. Markets much smarter on this than I, will wait into see how the stock prices react to this next week!
@Fierce__beast

Fierce_beast on X

For $CASY, let's say it grows earnings roughly 6% on average for the next 20 years, then 3% terminally. Maybe its 9% for the next 5 years, but gradually moves toward something like maturity of 3%, average let's say is 6%. What multiple would you currently pay on that earnings stream? Personally, i would pay no more than 25x for this. Add other considerations to the business, maybe you think it will grow faster or longer, adjust your multiple as you prefer.

Investor Letters

All letters

Microsoft's AI Boom Has A Cost

Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…

MSFT $4T
Yiannis Zourmpanos 2 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 4 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

MKL $24B
TSOH Investment Research 1 click

AMZN Q3 FY12/26 Earnings Review

Amazon reported $201.9 billion Q3 revenue and 39% AWS growth, while $220 billion in 2026 capex drove trailing free cash flow to a $42.4…

AMZN $2.9T
Cestrian Capital Research 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 275

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.